Odd-skipped related 1 plays a tumor suppressor role in ovarian cancer via promoting follistatin-like protein 1 transcription
- PMID: 35964260
- DOI: 10.1007/s13577-022-00767-5
Odd-skipped related 1 plays a tumor suppressor role in ovarian cancer via promoting follistatin-like protein 1 transcription
Abstract
Zinc-finger transcription factor odd-skipped related 1 (OSR1) is involved in the progression of certain types of cancers, via regulating the transcription of downstream genes. However, the function of OSR1 in ovarian cancer (OC) progression remains unclear. The present study aimed to explore the OSR1 expression pattern in OC tissues and cell lines. Functional assays were performed to explore the regulatory effects of OSR1 on OC cell growth, migration and invasion in vitro and in vivo. Results of the present study demonstrated that OSR1 was significantly downregulated in OC tissues compared with healthy ovarian tissues (P < 0.01). Moreover, SKOV-3 and OVCAR-3 cells with low OSR1 expression were used for functional studies, and results demonstrated that OSR1 overexpression suppressed cell growth by inhibiting cell cycle progression and inducing cell apoptosis in vitro. OC cells with higher OSR1 expression levels exhibited reduced levels of migration and invasion, when compared with the corresponding control. In addition, OSR1 expression in xenografts models resulted in diminished tumor volume and suppressed tumorigenesis. OSR1 enhanced follistatin-like protein 1 (FSTL1) expression at the transcriptional level through directly binding to the promoter of FSTL1, which was commonly reported to exert a tumor suppressor role in OC progression. Moreover, FSTL1 knockdown reversed the action of OSR1 overexpression in OC progression, including cell viability, migration, invasion, and apoptosis. In conclusion, these results indicated that OSR1 may function as a tumor suppressor through augmenting FSTL1 transcription in OC progression, suggesting that the OSR1/ FSTL1 axis may exhibit potential as a therapeutic target for OC therapy.
Keywords: FSTL1; Growth; OSR1; Ovarian cancer; Proliferation.
© 2022. The Author(s) under exclusive licence to Japan Human Cell Society.
Similar articles
-
OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer.Discov Oncol. 2023 Aug 29;14(1):159. doi: 10.1007/s12672-023-00778-0. Discov Oncol. 2023. PMID: 37642735 Free PMC article.
-
LncRNA MNX1-AS1 promotes ovarian cancer process via targeting the miR-744-5p/SOX12 axis.J Ovarian Res. 2021 Nov 17;14(1):161. doi: 10.1186/s13048-021-00910-0. J Ovarian Res. 2021. PMID: 34789303 Free PMC article.
-
Odd-skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer.J Pathol. 2014 Nov;234(3):302-15. doi: 10.1002/path.4391. Epub 2014 Aug 28. J Pathol. 2014. PMID: 24931004 Free PMC article.
-
Follistatin-like 1 in development and human diseases.Cell Mol Life Sci. 2018 Jul;75(13):2339-2354. doi: 10.1007/s00018-018-2805-0. Epub 2018 Mar 29. Cell Mol Life Sci. 2018. PMID: 29594389 Free PMC article. Review.
-
FSTL1: A double-edged sword in cancer development.Gene. 2024 May 15;906:148263. doi: 10.1016/j.gene.2024.148263. Epub 2024 Feb 10. Gene. 2024. PMID: 38346455 Review.
Cited by
-
The MexTAg collaborative cross: host genetics affects asbestos related disease latency, but has little influence once tumours develop.Front Toxicol. 2024 Apr 17;6:1373003. doi: 10.3389/ftox.2024.1373003. eCollection 2024. Front Toxicol. 2024. PMID: 38694815 Free PMC article.
-
Expression of the odd-2 Gene in C. elegans.MicroPubl Biol. 2023 Aug 25;2023:10.17912/micropub.biology.000967. doi: 10.17912/micropub.biology.000967. eCollection 2023. MicroPubl Biol. 2023. PMID: 37692086 Free PMC article.
-
OSR1 downregulation indicates an unfavorable prognosis and activates the NF-κB pathway in ovarian cancer.Discov Oncol. 2023 Aug 29;14(1):159. doi: 10.1007/s12672-023-00778-0. Discov Oncol. 2023. PMID: 37642735 Free PMC article.
References
-
- Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96. https://doi.org/10.3322/caac.21456 . - DOI - PubMed - PMC
-
- Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280–304. https://doi.org/10.3322/caac.21559 . - DOI - PubMed
-
- Yeung T-L, Leung CS, Yip K-P, Au Yeung CL, Wong STC, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. A review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309(7):C444–56. https://doi.org/10.1152/ajpcell.00188.2015 . - DOI - PubMed - PMC
-
- Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376–88. https://doi.org/10.1016/S0140-6736(13)62146-7 . - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous